The Ongoing Quest for Predictive Biomarkers in Chronic Obstructive Pulmonary Disease.
作者信息
Regard Lucile, Roche Nicolas, Burgel Pierre-Régis
机构信息
Université Paris Cité Inserm U1016, Institut Cochin Paris, France and Department of Respiratory Medicine Cochin Hospital, Assistance Publique - Hôpitaux de Paris Paris, France.
出版信息
Am J Respir Crit Care Med. 2023 Sep 1;208(5):511-513. doi: 10.1164/rccm.202306-0957ED.
Abstract
摘要
相似文献
1
The Ongoing Quest for Predictive Biomarkers in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中预测性生物标志物的持续探索
Am J Respir Crit Care Med. 2023 Sep 1;208(5):511-513. doi: 10.1164/rccm.202306-0957ED.
2
[Inflammatory lung and systemic disease].[炎症性肺部和全身性疾病]
Med Monatsschr Pharm. 2005 Jul;28(7):254-5.
3
[Modern therapy of COPD].[慢性阻塞性肺疾病的现代治疗]
Bull Acad Natl Med. 2004;188(1):67-74; discussion 74-5.
4
[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].罗氟司特：慢性阻塞性肺疾病治疗的新方法
Med Monatsschr Pharm. 2010 Jul;33(7):236-43.
5
Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease "Super Exacerbators".用于慢性阻塞性肺疾病“超级加重期”的口服磷酸二酯酶-4抑制剂
Am J Respir Crit Care Med. 2016 Sep 1;194(5):527-8. doi: 10.1164/rccm.201608-1566ED.
6
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.用于治疗哮喘和慢性阻塞性肺疾病的选择性磷酸二酯酶抑制剂。
Curr Opin Allergy Clin Immunol. 2002 Feb;2(1):61-7. doi: 10.1097/00130832-200202000-00010.
7
Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.慢性阻塞性肺疾病、炎症与磷酸二酯酶4抑制剂
Br J Hosp Med (Lond). 2006 Jul;67(7):370-4. doi: 10.12968/hmed.2006.67.7.21622.
8
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.用于治疗哮喘和慢性阻塞性肺疾病的磷酸二酯酶4抑制剂的最新进展。
J Med Chem. 2008 Sep 25;51(18):5471-89. doi: 10.1021/jm800582j. Epub 2008 Aug 8.
9
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.磷酸二酯酶-4抑制剂西洛司特（阿瑞吡坦）在慢性阻塞性肺疾病中的抗炎作用。
Am J Respir Crit Care Med. 2003 Oct 15;168(8):976-82. doi: 10.1164/rccm.200212-1490OC. Epub 2003 Jun 19.
10
COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.慢性阻塞性肺疾病、炎症及其受磷酸二酯酶4抑制剂的调节作用：是时候超越第一秒用力呼气量去看待问题了。
Chest. 2006 Jan;129(1):5-6. doi: 10.1378/chest.129.1.5.
引用本文的文献
1
Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives.探讨 COPD 的分子机制和生物标志物：当前进展和展望概述。
Int J Mol Sci. 2024 Jul 4;25(13):7347. doi: 10.3390/ijms25137347.
本文引用的文献
1
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.针对嗜酸性粒细胞计数提示 2 型炎症的 COPD，应用度普利尤单抗。
N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21.
2
Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary Disease.血清白细胞介素-8 作为预测慢性阻塞性肺疾病对磷酸二酯酶-4 抑制剂反应的指标。
Am J Respir Crit Care Med. 2023 Sep 1;208(5):559-569. doi: 10.1164/rccm.202301-0071OC.
3
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.慢性阻塞性肺疾病全球倡议组织2023年报告：《慢性阻塞性肺疾病全球倡议》执行摘要
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. doi: 10.1164/rccm.202301-0106PP.
4
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.吸入型双磷酸二酯酶 3/4 抑制剂治疗 COPD 患者：简短综述。
Int J Chron Obstruct Pulmon Dis. 2021 Aug 16;16:2363-2373. doi: 10.2147/COPD.S226688. eCollection 2021.
5
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.美泊利珠单抗治疗嗜酸性粒细胞相关 COPD：METREX 和 METREO 分析。
Int J Chron Obstruct Pulmon Dis. 2021 Jun 16;16:1755-1770. doi: 10.2147/COPD.S294333. eCollection 2021.
6
Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.COPD 中的嗜酸性粒细胞炎症：从炎症标志物到可治疗的特征。
Thorax. 2021 Feb;76(2):188-195. doi: 10.1136/thoraxjnl-2020-215167. Epub 2020 Oct 29.
7
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.在 COPD 中新型吸入型 PDE4 抑制剂 CHF6001 的疗效和安全性：PIONEER 研究。
Respir Res. 2020 Sep 22;21(1):246. doi: 10.1186/s12931-020-01512-y.
8
Machine Learning Characterization of COPD Subtypes: Insights From the COPDGene Study.慢性阻塞性肺疾病（COPD）亚型的机器学习特征：来自COPDGene研究的见解
Chest. 2020 May;157(5):1147-1157. doi: 10.1016/j.chest.2019.11.039. Epub 2019 Dec 28.
9
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.吸入性脂质体环丙沙星治疗非囊性纤维化支气管扩张症和慢性铜绿假单胞菌肺部感染患者（ORBIT-3 和 ORBIT-4）：两项 3 期随机对照试验。
Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15.
10
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.罗氟司特治疗重度慢性阻塞性肺疾病的应答影响因素：两项随机对照试验的汇总分析。
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC.
Zotero 插件